The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis and Whole-Body Glucose Homeostasis
Open accessAbstract
Summary Gluconeogenesis is critical for maintenance of euglycemia during fasting. Elevated gluconeogenesis during Type 2 Diabetes (T2D) contributes to chronic hyperglycemia. Pyruvate is a major gluconeogenic substrate and requires import into the mitochondrial matrix for channeling into gluconeogenesis. Here, we demonstrate that the Mitochondrial Pyruvate Carrier (MPC) comprising the Mpc1 and Mpc2 proteins is required for efficient regulation of hepatic gluconeogenesis. Liver-specific deletion of Mpc1 abolished hepatic MPC activity and markedly decreased pyruvate-driven gluconeogenesis and TCA cycle flux. Loss of MPC activity induced adaptive utilization of glutamine and increased urea cycle activity. Diet-induced obesity increased hepatic MPC expression and activity. Constitutive Mpc1 deletion attenuated the development of hyperglycemia induced by a high-fat diet. Acute, virally-mediated Mpc1 deletion after diet-induced obesity decreased hyperglycemia and improved glucose tolerance. We conclude that the MPC is required for efficient regulation of gluconeogenesis and that the MPC contributes to the elevated gluconeogenesis and hyperglycemia in T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A conditional knockout resource for the genome-wide study of mouse gene function
Skarnes, W. C., Rosen, B., West, A. P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A. O., Thomas, M., Harrow, J., Cox, T., et al. (2011) · Nature · doi:10.1038/nature10163 · Cited by 1,708
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 1×
“Although the precise mechanism remains without consensus, the well-characterized therapeutic effects of metformin provide a convincing demonstration of the potential efficacy of mitochondrial targeting (Madiraju et al., 2014; Miller et al., 2013).”
A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila , and Humans
Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y.-C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., et al. (2012) · Science · doi:10.1126/science.1218099 · Cited by 843
Self-citationThe mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors
Halestrap, A. P. (1975) · Biochemical Journal · doi:10.1042/bj1480085 · Cited by 543
FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
Potthoff, M. J., Boney-Montoya, J., Choi, M., He, T., Sunny, N. E., Satapati, S., Suino-Powell, K., Xu, H. E., Gerard, R. D., Finck, B. N., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.019 · Cited by 431 · cited 2×
“WT and Mpc1 LivKO mice were administered U13Clactate and -pyruvate by intraperitoneal injection as performed previously (Potthoff et al., 2011).”
Self-citationSchell, J. C., Olson, K. A., Jiang, L., Hawkins, A. J., Van Vranken, J. G., Xie, J., Egnatchik, R. A., Earl, E. G., DeBerardinis, R. J., & Rutter, J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.026 · Cited by 363 · cited 3×
“The decreased mitochondrial pyruvate utilization and increased glutaminolysis withMpc1 LivKO recapitulates aspects of the transformed metabolism observed in many cancers (Schell et al., 2014; Vacanti et al., 2014; Yang et al., 2014) and could provide a favorable metabolism for tumorigenesis during at-risk states such…”
Self-citationThiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308 · cited 1×
“More specifically, thiazolidinediones have recently been shown to inhibit MPC activity, presenting the possibility that a portion of their therapeutic effect could result from inhibition of the hepatic MPC (Divakaruni et al., 2013).”
Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats
Perry, R. J., Zhang, D., Zhang, X.-M., Boyer, J. L., & Shulman, G. I. (2015) · Science · doi:10.1126/science.aaa0672 · Cited by 283
Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier
Vacanti, N. M., Divakaruni, A. S., Green, C. R., Parker, S. J., Henry, R. R., Ciaraldi, T. P., Murphy, A. N., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.024 · Cited by 277 · cited 3×
“This is congruent with the increased fatty-acid oxidation induced in cultured myoblasts with MPC knockdown (Vacanti et al., 2014) and likely a general adaptive measure for impaired mitochondrial carbohydrate utilization.”
Cited by
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al.”
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
Guo, Y., Xie, Y.-Q., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 440
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure
Cluntun, A. A., Badolia, R., Lettlova, S., Parnell, K. M., Shankar, T. S., Diakos, N. A., Olson, K. A., Taleb, I., Tatum, S. M., Berg, J. A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.003 · Cited by 345
Self-citationControl of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism
Schell, J. C., Wisidagama, D. R., Bensard, C., Zhao, H., Wei, P., Tanner, J., Flores, A., Mohlman, J., Sorensen, L. K., Earl, C. S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3593 · Cited by 322
Self-citationCappel, D. A., Deja, S., Duarte, J. A. G., Kucejova, B., Iñigo, M., Fletcher, J. A., Fu, X., Berglund, E. D., Liu, T., Elmquist, J. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.03.014 · Cited by 242
Self-citationThe multifaceted pyruvate metabolism: role of the mitochondrial pyruvate carrier
Zangari, J., Petrelli, F., Maillot, B., & Martinou, J.-C. (2020) · Biomolecules · doi:10.3390/biom10071068 · Cited by 172
Pyruvate and metabolic flexibility: illuminating a path toward selective cancer therapies
Olson, K. A., Schell, J. C., & Rutter, J. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.01.002 · Cited by 154
Self-citationMetabolic Remodeling during Liver Regeneration
Caldez, M. J., Van Hul, N., Koh, H. W. L., Teo, X. Q., Fan, J. J., Tan, P. Y., Dewhurst, M. R., Too, P. G., Talib, S. Z. A., Chiang, B. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.09.020 · Cited by 133
Tompkins, S. C., Sheldon, R. D., Rauckhorst, A. J., Noterman, M. F., Solst, S. R., Buchanan, J. L., Mapuskar, K. A., Pewa, A. D., Gray, L. R., Oonthonpan, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.098 · Cited by 79
Self-citationThe yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state
Tavoulari, S., Thangaratnarajah, C., Mavridou, V., Harbour, M. E., Martinou, J., & Kunji, E. R. (2019) · The EMBO Journal · doi:10.15252/embj.2018100785 · Cited by 73
Oxaloacetic acid mediates ADP-dependent inhibition of mitochondrial complex II-driven respiration
Fink, B. D., Bai, F., Yu, L., Sheldon, R. D., Sharma, A., Taylor, E. B., & Sivitz, W. I. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005144 · Cited by 54
Self-citationMitochondrial pyruvate carrier function in health and disease across the lifespan
Buchanan, J., & Taylor, E. (2020) · Biomolecules · doi:10.3390/biom10081162 · Cited by 40
Self-citationTreating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, K. S., & Finck, B. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.017 · Cited by 39
Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer
Tavoulari, S., Schirris, T. J. J., Mavridou, V., Thangaratnarajah, C., King, M. S., Jones, D. T. D., Ding, S., Fearnley, I. M., & Kunji, E. R. S. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101469 · Cited by 38
Ceyzériat, K., Badina, A. M., Petrelli, F., Montessuit, S., Nicolaides, A., Millet, P., Savioz, A., Martinou, J.-C., & Tournier, B. B. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106623 · Cited by 18
Metadata
- Authors
- Gray, L. R., Sultana, M. R., Rauckhorst, A. J., Oonthonpan, L., Tompkins, S. C., Sharma, A., Fu, X., Miao, R., Pewa, A. D., Brown, K. S., Lane, E. E., Dohlman, A., Zepeda-Orozco, D., Xie, J., Rutter, J., Norris, A. W., Cox, J. E., Burgess, S. C., Potthoff, M. J., & Taylor, E. B.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 22
- Issue
- 4
- Pages
- 669-681
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W1762789982
- Cited by
- 224
- References
- 10
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.